Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era

Inclusion Criteria

• •Patients with histologically confirmed mucosal melanoma of head and neck (MMHN);
• •Tumor staged as stages III/IVA (according to the American Joint Committee on Cancer 7th edition staging system) arising from head and neck according to the radiology and clinical exam;
• •Prior local resection to primary tumor;
• •Radiologically confirmed (MRI, CT or PET-CT if necessary) no regional lymph node present, nor any evidence of distant metastasis;
• •Adequate marrow: white blood cell count of 4.0 × 109/L or more; absolute neutrophil of 2.0 × 109/L or more; haemoglobin concentrations of at least 90 g/L; platelet cell count of 100 × 109/L or more；
• •Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) \< 2.5×upper limit of normal (ULN)；
• •Adequate renal function: creatinine clearance rate of more than 60 mL/min;
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
• •Expected lifespan \> 3 months;
• •Patients must be informed of the investigational nature of this study and give written informed consent；
• •Patients must be consent to the follow-up till death, the study termination or the end of the study.